Literature DB >> 18395147

Hodgkin lymphoma: the follow-up of long-term survivors.

David C Hodgson1.   

Abstract

Hodgkin lymphoma (HL) is a disease that typically strikes children and young adults, with more than 80% of those affected being cured. Consequently, HL survivors can live for decades with the persistent and late-emerging effects of the disease and its treatment. The focus of this article is the long-term medical management of HL survivors, specifically those who are 5 years or more off therapy without evidence of relapse, when the focus of follow-up care shifts from detecting relapse to minimizing the morbidity associated with the late effects of treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18395147     DOI: 10.1016/j.hoc.2008.01.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  12 in total

1.  Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients.

Authors:  Michael T Milano; Huilin Li; Louis S Constine; Lois B Travis
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

Review 2.  Appropriate surveillance for late complications in patients in remission from Hodgkin lymphoma.

Authors:  Deborah L Darrington; Julie M Vose
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

3.  Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study.

Authors:  Michael T Milano; Huilin Li; Mitchell H Gail; Louis S Constine; Lois B Travis
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

4.  Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.

Authors:  Kuniaki Itoh; Tomohiro Kinoshita; Takashi Watanabe; Kenichi Yoshimura; Rumiko Okamoto; Takaaki Chou; Michinori Ogura; Masami Hirano; Hideki Asaoku; Mitsutoshi Kurosawa; Yoshiharu Maeda; Ken Omachi; Yukiyoshi Moriuchi; Masaharu Kasai; Kazunori Ohnishi; Nobuyuki Takayama; Yasuo Morishima; Kensei Tobinai; Harumi Kaba; Seiichiro Yamamoto; Haruhiko Fukuda; Masahiro Kikuchi; Tadashi Yoshino; Yoshihiro Matsuno; Tomomitsu Hotta; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2010-03-03       Impact factor: 2.490

5.  Survival patterns in patients with Hodgkin's lymphoma with a pre-existing hospital discharge diagnosis of autoimmune disease.

Authors:  Ola Landgren; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

Review 6.  The Role of Imaging with Cardiac Computed Tomography in Cardio-Oncology Patients.

Authors:  Barbora Pitekova; Sriram Ravi; Shimoli V Shah; Beata Mladosievicova; Stephen Heitner; Maros Ferencik
Journal:  Curr Cardiol Rep       Date:  2016-09       Impact factor: 2.931

7.  Fertility in female survivors of Hodgkin's lymphoma.

Authors:  Irene Biasoli; Simona Falorio; Stefano Luminari; Nelson Spector; Massimo Federico
Journal:  Rev Bras Hematol Hemoter       Date:  2012

8.  International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Authors:  Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace
Journal:  Qual Life Res       Date:  2017-11-10       Impact factor: 4.147

9.  Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis.

Authors:  Devon J Boyne; Alexis T Mickle; Darren R Brenner; Christine M Friedenreich; Winson Y Cheung; Karen L Tang; Todd A Wilson; Diane L Lorenzetti; Matthew T James; Paul E Ronksley; Doreen M Rabi
Journal:  Cancer Med       Date:  2018-08-15       Impact factor: 4.452

10.  Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease - a feasibility study.

Authors:  Maria T Vlachaki; Sanath Kumar
Journal:  J Appl Clin Med Phys       Date:  2010-01-28       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.